Can US differentiate pain? In #ACR23 Abs. #1388 PsA pts who have pain & inflammatory enthesitis on US, process pain differently than the US negative patients, despite the induction of pain or discomfort on all groups. Interesting finding. https://t.co/YcccLoQCBj @rheumnow https://t.co/o94bMwndxX

In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al) ⬆️freq AEs: nasopharyngitis & URTI Low EAIRs/100pt yrs for IBD, malignancies & MACE No new safety signals Reassuring data. #ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM

Quick curmudgeonly complaint WHY are we doing 316 week extensions? That's 292 weeks of $$$ data... for what? 1. Insufficient N to assess meaningful safety signals 2. Open label, no comparator It's just a very very expensive observational study @RheumNow #ACR23 Abstr1434 https://t.co/Thj1XjeAn1

Proof-of-concept study: when PsA pts w/Achilles enthesitis & +US findings underwent pain induction, they showed ⬆️activity in the OBF gyrus, ant cing, left PCG, SMG, STG an left PC lobule vs. US- grp. PsA pts w/+US process pain differently than US- #ACR23 ABST1388 @RheumNow https://t.co/ScXA17LHPa

Pooled safety analysis of 48 phase II/III/IV trials on secukinumab for tx of PsO, PsA and axSpA Well tolerated No new long term safety signals IBD, malginancy, MACE remain low @RheumNow #ACR23 Abs#1436 https://t.co/6dzdO5Vpuc

Long-term safety of risankizumab in PsA and PsO pts Over 5k pts, over 4 years Rates of AEs remained low malignancy incidence remains low @RheumNow #ACR23 Abs#1422 https://t.co/GBFke3XmQD

Patient perspective: PP09 at #ACR23 "Mindfulness helps me experience less suffering over pain" in patient with PsA + fibromyalgia. ⭐️Consider recommending mindfulness training such as mindfulness based stress reduction @RheumNow https://t.co/DHwduvTPZL

The places to look for #enthesitis in #PsA in foot/ankle #ACR2023 https://t.co/KxD7i5l5gS